BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/17/2022 3:19:26 AM | Browse: 414 | Download: 1304
 |
Received |
|
2021-12-29 14:28 |
|
Peer-Review Started |
|
2021-12-29 14:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-01-25 06:22 |
|
Revised |
|
2022-02-14 14:26 |
|
Second Decision |
|
2022-04-29 03:12 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-04-30 07:37 |
|
Articles in Press |
|
2022-04-30 07:37 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-04-24 23:18 |
|
Typeset the Manuscript |
|
2022-06-01 13:43 |
|
Publish the Manuscript Online |
|
2022-06-17 03:19 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hua-Hua Yang, Yi Huang, Xu-Chun Zhou and Ruo-Nan Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xu-Chun Zhou, MD, Professor, Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. chqxchzh@163.com |
| Key Words |
Crohn disease; Adalimumab; Infliximab; Clinical efficacy; Adverse effects; Meta-analysis |
| Core Tip |
Differences in immunogenicity and route of administration among adalimumab (ADA) and infliximab (IFX) allow for potential variability in therapeutic properties and efficacy. However, clear recommendations have been limited due to a lack of head-to-head comparison. We conducted a meta-analysis to synthesize current results and assessed the efficacy and safety between ADA and IFX. The result showed that both have similar clinical benefits for anti-tumor necrosis factor-alpha naive or non-naive Crohn’s disease patients. Overall adverse events rate is higher in patients in the IFX group. ADA and IFX can be chosen on a possible history of adverse events and patients’ compliance. |
| Publish Date |
2022-06-17 03:19 |
| Citation |
Yang HH, Huang Y, Zhou XC, Wang RN. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis. World J Clin Cases 2022; 10(18): 6091-6104 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i18/6091.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i18.6091 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
